Navigation Links
Blocking signaling protein prevents prostate cancer spread, Jefferson scientists find
Date:6/2/2008

(PHILADELPHIA) Researchers at the Kimmel Cancer Center at Jefferson in Philadelphia have shown that by blocking a signaling protein, they can prevent prostate cancer cells from metastatic dissemination. The work opens the door to future studies examining the protein as a target for therapies aimed at keeping prostate cancer at bay.

In a series of experiments in both the laboratory and animal models, Marja Nevalainen, M.D., Ph.D., associate professor of Cancer Biology at Jefferson Medical College of Thomas Jefferson University and her co-workers found that the protein, Stat3, is key to the metastatic progression of prostate cancer. Dr. Nevalainen's group reports its findings in the June 2008 issue of the American Journal of Pathology.

According to Dr. Nevalainen, previous studies have shown that Stat3 is very active in metastatic prostate cancer, and the protein has been linked to cancer metastasis in several different cancer types. Because metastatic prostate cancer lacks effective therapies, understanding the molecular changes involved is critical.

To clarify Stat3's role in prostate cancer progression, she and her co-workers performed several studies. In one case, the scientists used an antibody for Stat3, for example, to show that it is activated in 77 percent of lymph nodes and 66 percent of bone metastases in human prostate cancer. In another experiment, the scientists prompted mouse prostate cancer cells to overproduce the normal Stat3 protein by delivering it through a virus vehicle. They saw a dramatic increase in prostate cancer metastases compared to controls.

Specifically, in mice lacking a working immune system, they showed that Stat3 caused a 33-fold increase in metastases.

"This is the first proof that Stat3 may have a major effect on metastatic dissemination of prostate cancer," Dr. Nevalainen says. "Stat3 now becomes a potential drug target to interfere with the metastatic progression of prostate can
'/>"/>

Contact: Steve Benowitz
Steven.Benowitz@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Blocking the effect of inflammation-causing cells lowered prostate cancer cells invasion
2. Blocking protein kills prostate cancer cells, inhibits tumor growth, Jefferson scientists find
3. Blocking Potent Oxidant Could Prevent Morphine Tolerance
4. Secrets of cellular signaling shed light on new cancer stem cell therapies
5. Researchers learn how signaling molecule orchestrates breast cancers spread
6. Model offers new understanding of cell signaling
7. Signaling protein helps limit damage in heart attack, Jefferson scientists show
8. St. Jude finds signaling system that halts the growth of a childhood brain cancer
9. Scientists shed light on long-distance signaling in developing neurons
10. Cooper Clinic at Craig Ranch Opens Signaling the Next Phase of CooperLife Health-Focused Residential Community in McKinney
11. Emory researchers identify signaling protein for multiple myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... 2015 For those people who are ... Mesothelioma Applied Research Foundation (Meso Foundation) will ... 3, starting at 9:30 AM. , The live broadcast ... broadcast can be accessed through any browser on a ... The Symposium is a unique event that covers important ...
(Date:2/28/2015)... Dr. Perry Patel , a ... recently announced a special offer for the Zoom!® Chairside ... for new and established patients at his Pismo Beach dentist office. ... white smile, Dr. Patel and his staff are offering ... from the regular price of $450. , Zoom! whitening ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 How ... Supportive? Strategic? , There are all kinds of ... To raise awareness of the advantages and applications ... PeopleKeys is launching a new product this spring ... better understand the connection between personality type, leadership, ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Developers of ... of a new overlay plugin for Final Cut Pro X ... , “FCPX Overlay Chromatic gives users total control over 6k ... Austin, CEO of Pixel Film Studios. “FCPX Overlay Chromatic was ... easy to use interface.” , FCPX Overlay Chromatic Grunge 6K ...
(Date:2/28/2015)... 2015 Memphis, TN: MedixSafe has retracted ... a new security reader named Guardian 2. The ... a new biometric scanner that significantly increases the ... the new biometric scanner provides fast and easy ... MedixSafe narcotics lockers with Vanguard technology ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Cancer Research Foundation Broadcasting Symposium Live 2Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2Health News:PeopleKeys Launches The Leadership Report 2Health News:PeopleKeys Launches The Leadership Report 3Health News:Pixel Film Studios released a new overlay plugin entitled FCPX Overlay Chromatic Grunge 6K exclusively for Final Cut Pro X users 2Health News:New Name Announced For Newest MedixSafe Readers – MedixSafe Vanguard 2
... CARLOS, Calif., Nov. 7 Nektar,Therapeutics (Nasdaq: NKTR ... quarter that ended September 30, 2007. Revenue totaled ... to,$58.6 million in the third quarter of 2006. For ... revenue of $207.3 million,compared to $147.8 million in the ...
... Nov. 7 Rapid Pathogen Screening Inc.,(RPS) -- ... ocular,diseases -- announced today that the American Medical ... code that will cover the,RPS Adeno Detector(TM), effective ... code,for "Infectious agent antigen detection by immunoassay with ...
... 7 Mesa Laboratories,Inc. (Nasdaq: MLAB ) today reported ... and six months ended September 30, 2007. Highlights: ... * Second quarter net income increases 40% ... the second quarter of fiscal 2008, net sales increased 16 ...
... Corrective cardiac surgery is not to blame, study suggests , , ... in babies born with certain heart defects, new research shows. ... delay found in premature infants, the researchers added. , Babies ... developmental delays, but whether the delays were due to the ...
... This past weekend study,results on "Molecular Breast ... at the Nuclear Science Symposium and Medical,Imaging Conference ... laboratory study was to evaluate the performance of ... in which,the two imaging detectors are positioned on ...
... 7 Today, the release of,Emerging Answers 2007: ... Sexually Transmitted Disease, a report authored by Douglas,Kirby, ... once,again, that the $1.5 billion federal and state ... money., The report, commissioned by the National ...
Cached Medicine News:Health News:Nektar Therapeutics Announces Third Quarter 2007 Financial Results 2Health News:Nektar Therapeutics Announces Third Quarter 2007 Financial Results 3Health News:Nektar Therapeutics Announces Third Quarter 2007 Financial Results 4Health News:Nektar Therapeutics Announces Third Quarter 2007 Financial Results 5Health News:Nektar Therapeutics Announces Third Quarter 2007 Financial Results 6Health News:Nektar Therapeutics Announces Third Quarter 2007 Financial Results 7Health News:American Medical Association Clears Path for Adenoviral Conjunctivitis - 'Pink Eye' - Detector 2Health News:Mesa Labs Reports Higher Quarterly Sales and Earnings 2Health News:Mesa Labs Reports Higher Quarterly Sales and Earnings 3Health News:Mesa Labs Reports Higher Quarterly Sales and Earnings 4Health News:Mesa Labs Reports Higher Quarterly Sales and Earnings 5Health News:Heart Defects Can Delay Baby's Brain Development 2Health News:Heart Defects Can Delay Baby's Brain Development 3Health News:Heart Defects Can Delay Baby's Brain Development 4Health News:Dilon Technologies Explores Improvements in Molecular Breast Imaging 2Health News:Dilon Technologies Explores Improvements in Molecular Breast Imaging 3Health News:New Study - Same Verdict 2
(Date:2/27/2015)... YORK , Feb. 27, 2015 Securities ... the board of Salix Pharmaceuticals, Ltd. (NASDAQ: ... $158.00 per share. Concerned SLXP investors are encouraged to ... The investigation focuses upon the shareholder ... agreement, Salix shareholders would receive only $158.00 per share ...
(Date:2/27/2015)... Report Details   ... R&D progress, and predicted revenues ,Where is the market ... commercial prospects for this market and related technologies? Visiongain,s ... trends to 2025, discussing data, opportunities and prospects. ... regenerative medicine : cell-based therapies that aim to restore ...
(Date:2/27/2015)... , Feb. 27, 2015  Organovo Holdings, ... company focused on delivering breakthrough 3D bioprinting technology, ... and Chief Executive Officer, will present live at ... invite you to join us for this Company ... updates on our commercial launch of the exVive3D ...
Breaking Medicine Technology:Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4
EZ-PSA is a one-step immunoassay for the rapid, qualitative determination of human Prostate Specific Antigen (PSA) in whole blood. The test is intended for professional use as an aid in the diagnosis...
... derives its name from its first known ... The majority of PSA circulates bound to ... concentrations of PSA are elevated in patients ... and prostatitis [1-3]. In addition, PSA serum ...
... of Vision and Contrast Sensitivity. The ... and glare luminance levels for accurate ... with/without glare and background luminance Comply ... standards. All Light Levels Microprocessor Controlled ...
Contrast Sensitivity is Recognized as a Valuable Tool for Measuring Functional Vision Loss Caused by Early Eye Disease. Distance Test S.W.C.T. 201: Size 27in x 37 in (68.58cm x 93.98cm),Can be Wal...
Medicine Products: